Clinic Directory — coming soon. Are you an Australian peptide clinic?Apply to be listed →
Independent · Australian · Education only — not medical adviceAboutEditorial standardsHow we review
HomeUpdatesCompounded peptides remain under tighter scrutiny
Compounding1 June 2026

Compounded peptides remain under tighter scrutiny

The regulatory direction on compounded peptides has been toward tighter controls. If you’re told a peptide is available “through compounding”, that pathway is narrower than it used to be.

Compounding is the preparation of a medicine for an individual patient against a prescription. It has never been a mechanism for mass-supplying unapproved products, and the rules around certain compounded peptides have been progressively tightened.

For consumers, the practical takeaway is simple: “we compound it” is not the same as “it’s approved”. A legitimate prescriber can explain exactly which lawful pathway applies to your situation.

Always confirm the current position directly with the TGA, as compounding rules can change.

Sources & further reading

Written by The Peptides.au editorial team
Editorial review Checked against current TGA, ARTG and AHPRA public guidance
Last updated 1 June 2026

This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.